The only stimulus tested that reduced sCTLA-4 production, and the
one on which the earlier literature was based, was high-concentration anti-CD3 mAb [20, 21]. This may reflect the nonphysiological avidity of T-cell ligation by anti-CD3, since low titres of the mAb increased sCTLA-4 secretion. Not only was sCTLA-4 produced as part of most T-cell responses in vitro, but it was also shown to have potent regulatory properties, since blockade with an sCTLA-4–selective mAb Regorafenib purchase resulted in marked increases in Th1 and Th17 effector activities. The lack of any such effect on resting cells, despite background production of sCTLA-4, is consistent with previous observations of mCTLA-4, which suggested that its regulatory function is also
dependent upon TCR engagement [37, 38]. Conventional anti-CTLA-4 antibodies, which can bind both mCTLA-4 and sCTLA-4, have been proven to induce productive antitumor responses and now provide a therapy option for treatment of malignant melanoma [30–32, 34]. The rationale behind anti-CTLA-4 Ab therapy is that it enhances immune responses against tumor Ags primarily by enhancing tumor-specific effector T-cell responses. https://www.selleckchem.com/products/VX-809.html With regard to boosting effector T-cell responses, however, blockade of CTLA-4 is surprisingly inconsistent; with several groups reporting that blockade of mCTLA-4 interaction with B7 ligands in the presence of TCR coactivation can actually inhibit T-cell activation [39-44]. In particular, experiments
in which cell surface cross-linking of mCTLA-4 occurs demonstrate the capacity of anti-CTLA-4 antibodies to inhibit T-cell responses. It is likely that cross-linking mCTLA-4 provides an agonist signal to the T cell, stimulating cell-intrinsic inhibitory signaling mediated via its cytoplasmic domain. Indeed, there is good evidence that cell extrinsic regulatory effects of CTLA-4 OSBPL9 can be mediated solely through the extracellular B7 binding domain of the molecule [45]. For example, recombinant soluble CTLA4-Ig, a fusion of the CTLA-4 extracellular domain with immunoglobulin has been shown to rescue CTLA-4−/− mice from fatal lymphoproliferative disease [46] and to induce APC regulatory mechanisms such as induction of the T-cell inhibitory IDO enzyme [17]. Further, selective knockout of the cytoplasmic domain of CTLA-4 revealed that while it is important for mediating cell intrinsic TCR hyposignaling, it was not required for CTLA-4–dependent, Treg-cell–mediated suppressive effects. In our experiments, selective mAb blockade of sCTLA-4 had more reliable and marked effects in enhancing human T-cell responses in vitro than any of the pan-specific anti-human CTLA-4 antibodies tested, emphasizing the possibility of a major contribution to regulation by the soluble isoform.